Glucagon-like peptide-1 receptor agonists in neoplastic diseases

被引：1
作者：
Ji, Lisan [1 ]
He, Xianzhen [2 ]
Min, Xinwen [1 ]
Yang, Handong [1 ]
Wu, Wenwen [3 ]
Xu, Hao [1 ]
Chen, Jun [1 ,4 ]
Mei, Aihua [1 ]
机构：
[1] Hubei Univ Med, Sinopharm Dongfeng Gen Hosp, Hubei Clin Res Ctr Hypertens, Hubei Key Lab Wudang Local Chinese Med Res, Shiyan, Peoples R China
[2] Hubei Univ Med, Renmin Hosp, Childrens Med Ctr, Shiyan, Hubei, Peoples R China
[3] Hubei Univ Med, Sch Publ Hlth, Shiyan, Hubei, Peoples R China
[4] Hubei Univ Med, Virol Key Lab Shiyan City, Shiyan, Peoples R China
来源：
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词：
GLP-1RA; tumor diseases; function; mechanism; agonists; PANCREATIC-CANCER CELLS; THYROID C-CELLS; DIABETES-MELLITUS; INSULIN-SECRETION; INHIBITS GROWTH; GLP-1; ANALOG; ACTIVATION; EXENDIN-4; RISK; APOPTOSIS;
D O I：
10.3389/fendo.2024.1465881
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids. It has also been shown that it can influence the proliferation and survival of cells and has a certain effect on the prognosis of some neoplastic diseases. In this study, the potential effects of GLP-1RAs on the occurrence and development of tumors were reviewed to provide new ideas for the prevention and treatment of tumors in patients.
引用
收藏
页数：9
相关论文
共 98 条
[1]   Exendin-4 inhibits high glucose-induced oxidative stress in retinal pigment epithelial cells by modulating the expression and activation of p66Shc [J].
Al Sabaani, Nasser .
CUTANEOUS AND OCULAR TOXICOLOGY, 2021, 40 (03) :175-186
[2]   Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer [J].
Andersen, Dana K. ;
Korc, Murray ;
Petersen, Gloria M. ;
Eibl, Guido ;
Li, Donghui ;
Rickels, Michael R. ;
Chari, Suresh T. ;
Abbruzzese, James L. .
DIABETES, 2017, 66 (05) :1103-1110
[3]   Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 [J].
Arakawa, Masayuki ;
Mita, Tomoya ;
Azuma, Kosuke ;
Ebato, Chie ;
Goto, Hiromasa ;
Nomiyama, Takashi ;
Fujitani, Yoshio ;
Hirose, Takahisa ;
Kawamori, Ryuzo ;
Watada, Hirotaka .
DIABETES, 2010, 59 (04) :1030-1037
[4]   A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials [J].
Aroda, Vanita R. .
DIABETES OBESITY & METABOLISM, 2018, 20 :22-33
[5]  
Ast J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14309-w
[6]   GLP-1 Receptor Expression Within the Human Heart [J].
Baggio, Laurie L. ;
Yusta, Bernardo ;
Mulvihill, Erin E. ;
Cao, Xiemin ;
Streutker, Catherine J. ;
Butany, Jagdish ;
Cappola, Thomas P. ;
Margulies, Kenneth B. ;
Drucker, Daniel J. .
ENDOCRINOLOGY, 2018, 159 (04) :1570-1584
[7]   Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes what hepatologists need to know [J].
Barritt, A. Sidney ;
Marshman, Emma ;
Noureddin, Mazen .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (08) :944-959
[8]   GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK [J].
Beiroa, Daniel ;
Imbernon, Monica ;
Gallego, Rosalia ;
Senra, Ana ;
Herranz, Daniel ;
Villarroya, Francesc ;
Serrano, Manuel ;
Ferno, Johan ;
Salvador, Javier ;
Escalada, Javier ;
Dieguez, Carlos ;
Lopez, Miguel ;
Fruehbeck, Gema ;
Nogueiras, Ruben .
DIABETES, 2014, 63 (10) :3346-3358
[9]   GLP-1 Receptor Agonists and the Risk of Thyroid Cancer [J].
Bezin, Julien ;
Gouverneur, Amandine ;
Penichon, Marine ;
Mathieu, Clement ;
Garrel, Renaud ;
Hillaire-Buys, Dominique ;
Pariente, Antoine ;
Faillie, Jean-Luc .
DIABETES CARE, 2023, 46 (02) :384-390
[10]  
Bobustuc George C, 2018, Oncotarget, V9, P29727, DOI 10.18632/oncotarget.25696
12345678910